Application

Research CategoryApoptosis & Cancer

Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected SSTR5/SS5R (P335L mutation) in normal human pancreas and human pancreatic cancer tissues.

Western Blotting Analysis: A representative lot from an independent laboratory detected SSTR5/SS5R (P335L mutation) in HA-SSTR5 (P335L mutation) transfected HEK293 cell lysate (Zhou, G., et al. (2011). World J Surg. 35(8):1715-1724.).

Immunocytochemistry Analysis: A representative lot from an independent laboratory detected SSTR5/SS5R (P335L mutation) in Panc-1 cells expressing SSTR5 (P335L mutation), and not in Panc-1 cells or CAPAN-1 cells expressing wild type SSTR5 (Zhou, G., et al. (2011). Surgery. 150(6):1136-1142.).

Western Blotting Analysis: A representative lot from an independent laboratory detected SSTR5/SS5R (P335L mutation) in CAPAN-1 and Panc-1 cell lysates expressing SSTR5/SS5R (P335L mutation) (Zhou, G., et al. (2011). Surgery. 150(6):1136-1142.).

Research Sub CategoryApoptosis - Additional

This Anti-SSTR5/SS5R (P335L mutation) Antibody, clone D2F2 is validated for use in western blotting, ICC & IHC for the detection of SSTR5/SS5R (P335L mutation).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Somatostatin receptor subtype 5 (SSTR5) mediates the inhibitory effect of somatostatin on insulin expression/secretion and cell proliferation. A number of single nucleotide polymorphisms (SNPs) of SSTR5 have been identified, including P335L, a nonsynonymous SNP located in the protein C-terminal region and encrypted by the codon CCG (proline) or the codon CTG.

SSTR5 SNP P335L widely exists in the human population, in patients with pancreatic cancer, and is race-dependent. SSTR5 SNP P335 overexpression resulted in cellular proliferation and PDX-1 overexpression in human pancreatic cancer cells. Its overexpression also blocked the inhibitory effect of SSTR5-specific analogs on human pancreatic cancer cell proliferation and on glucose-stimulated insulin secretion from mouse insulinoma cells. SSTR5 P335L is a hypofunctional protein with a potentially harmful effect on function, as well as potential latent effect, and therefore it could affect the clinical response to somatostatin analog therapy for patients with pancreatic cancer.

Immunogen

Linear peptide corresponding to human SSTR5/SS5R (P335L mutation).

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Protein G Purified

Format: Purified

Quality

Evaluated by Western Blotting in Panc-1 cell lysate and Mia Paca-2 cell lysate.

Western Blotting Analysis: 2 µg/mL of this antibody detected SSTR5/SS5R (P335L mutation) in 10 µg of Panc-1 cell lysate and not in Mia Paca-2 cell lysate.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~39 kDa observed